Terazosin EP Impurity B
| Product Name | Terazosin EP Impurity B |
|---|---|
| Alternate Names | Terazosin Impurities, Impurities of Terazosin |
| CAT No. | CS-O-08279 |
| CAS No. | 1177261-73-2 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 388.42 g/mol |
| Mol. For. | C₁₉H₂₄N₄O₅ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Terazosin |
| Smileys | COC1=C(C=C2C(=C1)C(=O)NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)OC |
| Canonical Smiles | COC1=C(C=C2C(=C1)C(=O)NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)OC |
| InchIKey | SOPCVLMNPKFJKQ-UHFFFAOYSA-N |
| Inchl | InChI=1S/C19H24N4O5/c1-26-15-10-12-13(11-16(15)27-2)20-19(21-17(12)24)23-7-5-22(6-8-23)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H,20,21,24) |
| IUPAC | 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]-3H-quinazolin-4-one |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Terazosin EP Impurity B is a significant organic compound that is used as an impurity in the manufacturing of Terazosin, a medication used for the treatment of hypertension or high blood pressure. The impurity is also known as (2R, 3R)-2-(2-{[2-(4-Amino-6, 7-dimethoxyquinazolin-2-yl) hydrazinyl] carbonyl} cyclohexylamino) butanoic acid. It is a white to off-white powder, and its molecular formula is C21H33N5O5.
The chemical structure of Terazosin EP Impurity B is closely related to Terazosin, which is a selective alpha-1 blocker medication. The impurity is formed during the synthesis of Terazosin, and it is essential to control and monitor the levels of impurities to ensure the quality and efficacy of the final product.
Terazosin EP Impurity B is a potential mutagenic impurity and a known genotoxic impurity. Therefore, the impurity level in the final product must be controlled and minimized to ensure the safety of patients who use Terazosin medication. The impurity is also subjected to strict regulatory guidelines, and its levels must be below the acceptable daily intake (ADI) limit set by regulatory authorities.
In conclusion, Terazosin EP Impurity B is a crucial impurity in the manufacturing of Terazosin medication, and its levels must be carefully controlled and monitored to ensure the safety and quality of the final product.
Get an Instant Quote
Related Compounds
Terazosin EP Impurity H | Terazosin EP Impurity C | Terazosin impurity | Terazosin EP Impurity D | N-Nitroso Terazosin EP Impurity N | Terazosin EP Impurity E | Terazosin Impurity 6 | Terazosin related compound C |